Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to begin a randomized, double-blind, placebo-controlled Phase 2 trial of Lucid-MS in people with multiple sclerosis. The FDA clearance marks a significant step for the company's lead drug candidate, which is designed to inhibit peptidyl arginine deiminase 2 (PAD2) and target demyelination rather than broadly suppressing the immune system. This approach could offer a new treatment paradigm for MS, a chronic neurological disease that affects millions worldwide and currently has no cure.
Lucid-MS, also known as Lucid-21-302, is a patented first-in-class drug candidate that previously completed Phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability. The Phase 2 trial will assess the drug's efficacy and safety in patients with MS. If successful, Lucid-MS could address a major unmet need by potentially preventing or reversing myelin degradation, the underlying mechanism of MS. This news is particularly important for patients who have not responded adequately to existing therapies, which often focus on immune suppression and carry significant side effects.
In addition to the clinical milestone, Quantum BioPharma is engaged in a parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School involving a PET imaging tracer designed to quantify demyelination. This collaboration could enhance the understanding of MS progression and provide valuable biomarkers for future trials. The company's efforts have also attracted analyst attention, with Rodman & Renshaw initiating coverage on Quantum BioPharma with a Buy rating and an $8 price target. The editorial coverage placed Quantum alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology, and neurological diseases.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 19.84% as of March 31, 2026, and royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The FDA clearance and the upcoming Phase 2 trial represent a critical inflection point for Quantum BioPharma and could have broader implications for the MS treatment landscape. With a novel mechanism of action, Lucid-MS has the potential to become a first-in-class therapy if approved. The news also highlights the company's growing profile in the biotech sector, as evidenced by analyst coverage and the recent editorial spotlight. For investors, the progress of Lucid-MS could serve as a key catalyst for the stock, while for patients, it offers hope for a new treatment option that targets the root cause of MS rather than just managing symptoms.
To view the full press release, visit https://ibn.fm/cwPHa. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
